In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Best of the Blog: IN VIVO February 2009

Executive Summary

A roundup of our best February blog posts not covered elsewhere in the magazine includes Biotech's Winter and the March of the EarnOuts; Infant formula division Mead Johnson milks investors of $720 million in IPO; Dont Come Knockin' on my Door: Survey shows physicians restrict drug rep access.

You may also be interested in...



Lundbeck Looks To Replace Lexapro Earnings Through Ovation Purchase

Acquisition will enhance Lundbeck’s CNS pipeline and add a needed U.S. specialty sales force.

Endo Branches Out With $370M Indevus Acquisition

Re-submission of Nebido NDA in the wings, sales force will target general practitioners with urology, endocrinology drugs to general practitioners.

Venture Prepares for Structured Acquisitions

With Big Pharma content to sit on the sidelines and wait as biotech company valuations continue their fall, the M&A activity that does take place is likely to place a premium on hedging risk. And, say venture investors, that means structured acquisitions of biotech firms are likely to increase as pharmaceutical acquirers gain more leverage over cash-strapped firms in deal negotiations.

Related Content

Related Companies

UsernamePublicRestriction

Register

ID1132115

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel